Spotlight On... Robotic surgery player Titan licenses tech from Mayo Clinic; Xeltis kicks Series B up to $32.4M; Canadian co heads to FDA with duodenoscope sterilizer; and more...

Robotic surgery aspirant Titan Medical it is licensing know-how and technology from the Mayo Clinic to improve its development-stage Sport Surgical System for performing colorectal surgery. The technology was developed by Dr. David Larson, chair of colorectal surgery at the Mayo Clinic. "We are very excited to further develop procedures, know-how and instruments for colorectal surgery as we move even closer to the commercialization of the Sport Surgical System," said Titan Medical CEO John Hargrove, in a statement. The company expects to launch the device internationally in late 2016, and in 2017 in the U.S. Titan is one of a number of companies looking to challenge Intuitive Surgical's ($ISRG) DaVinci for supremacy in the minimally invasive surgery arena, including bigwigs Johnson & Johnson ($JNJ) and Medtronic ($MDT). Read the release | More about the device

@FierceMedDev: NYU researchers roll out ResearchKit app as part of concussion-monitoring study. Article | Follow @FierceMedDev

@EmilyWFierce: In this week's Dx Digest, $ILMN makes waves in China and $LH buys a women's health lab. More | Follow @EmilyWFierce

> Bioabsorbable cardiovascular valves and vessels player Xeltis has added €3 million ($3.2 million) to bring its Series B round to €30 million ($32.4 million). More

> Alpheon has completed its acquisition of Lensar, maker of Femtosecond Lasers Systems (FLS), in order to expand into ophthalmology. More

> Canada's TSO3 has won a claim specifically to sterilize the Olympus TJF-Q180V Duodenoscope from that country's regulator. It will start talks with the FDA early next year to aim for the U.S. The ineffective cleaning of duodenoscopes has been an ongoing issue for years. More

Biotech News

@FierceBiotech: Biotech bad boy Martin Shkreli faces a new set of angry foes: federal prosecutors. News | Follow @FierceBiotech

@JohnCFierce: Gilead steps in to replace AbbVie with $2B Galapagos collaboration. News | Follow @JohnCFierce

@DamianFierce: it is with solemn humility that I now accept the mantle of Biotech's Bad Boy. thank you. | Follow @DamianFierce

> AstraZeneca bets $7B on Acerta's potential blockbuster cancer treatment. Report

> Kahr Medical leans on Korean VCs to raise $12M for oncology R&D. Story

> University of California commits $250M for a new tech venture fund for biotech, more. Article

Pharma News

@FiercePharma: Toxin from sea algae impacts memory, behavior in California sea lions: Study. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Mylan wants some payback for plants it bought from Strides that have been cited by FDA. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca shrugs off pharma's emerging markets slowdown, but Lilly's suffering. Article | Follow @CarlyHFierce

> GSK's Avandia is free and clear at the FDA, 8 years after heart-safety controversy began. Story

> Top-earning directors on the S&P 500? Regeneron and Endo, at $1.4M and up. Report

> FBI arrests controversial Turing CEO Martin Shkreli on securities fraud charges. Article

CRO News

> PPD reportedly on the block for $8B. Report

> Recipharm signs on to manufacture an in-development cancer drug, investing in a Swedish biotech. Article

> On the rebound, AMRI trades $52M for a testing firm. News

Pharma Manufacturing News

> AstraZeneca shifts supply chain strategy from air to sea freight shipments. Report

> GSK opens Australia pilot plant to test blow-fill-seal technology on vaccines. Article

> WuXi and PRA canceling joint venture in China. Item

> Deadline looms to meet new label and insert requirements in Taiwan. More

> WuXi to sell AstraZeneca China's largest biologics plant for $100M. News

Pharma Asia News

> Indian healthcare IPOs raise $300M. Item

> Don't count India out yet in biosimilars race, Quintiles exec says. More

> YiChang IPO joins other drug companies in tough IPO market. Report

> Taiwan sets June 2016 deadline on new packaging, insert rules. Story

> WuXi venture unit raises $290M for 'find in U.S., build in China' venture fund. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.